Compare Elder Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA DIVIS LABORATORIES ELDER PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x -0.2 31.8 - View Chart
P/BV x 0.1 7.2 1.4% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ELDER PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
DIVIS LABORATORIES
Mar-18
ELDER PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3801,142 33.3%   
Low Rs188533 35.3%   
Sales per share (Unadj.) Rs491.2146.6 335.1%  
Earnings per share (Unadj.) Rs-3.233.0 -9.6%  
Cash flow per share (Unadj.) Rs14.438.4 37.5%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs376.5222.8 169.0%  
Shares outstanding (eoy) m20.54265.47 7.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.65.7 10.1%   
Avg P/E ratio x-89.325.3 -352.1%  
P/CF ratio (eoy) x19.721.8 90.4%  
Price / Book Value ratio x0.83.8 20.1%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m5,833222,318 2.6%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m2,1794,561 47.8%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m10,08938,915 25.9%  
Other income Rs m2571,134 22.6%   
Total revenues Rs m10,34640,049 25.8%   
Gross profit Rs m-79212,617 -6.3%  
Depreciation Rs m3611,425 25.4%   
Interest Rs m2,75613 20,724.1%   
Profit before tax Rs m-3,65312,313 -29.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1253,543 3.5%   
Profit after tax Rs m-658,770 -0.7%  
Gross profit margin %-7.832.4 -24.2%  
Effective tax rate %-3.428.8 -11.9%   
Net profit margin %-0.622.5 -2.9%  
BALANCE SHEET DATA
Current assets Rs m9,24045,351 20.4%   
Current liabilities Rs m9,9986,507 153.6%   
Net working cap to sales %-7.599.8 -7.5%  
Current ratio x0.97.0 13.3%  
Inventory Days Days46127 36.6%  
Debtors Days Days6095 63.0%  
Net fixed assets Rs m10,12421,160 47.8%   
Share capital Rs m206531 38.7%   
"Free" reserves Rs m5,58258,625 9.5%   
Net worth Rs m7,73459,156 13.1%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88267,832 33.7%  
Interest coverage x-0.3926.8 -0.0%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 76.9%   
Return on assets %11.812.9 90.8%  
Return on equity %-0.814.8 -5.7%  
Return on capital %22.320.8 107.1%  
Exports to sales %3.00-   
Imports to sales %0.421.8 2.0%   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m438,485 0.5%   
Fx inflow Rs m30732,359 0.9%   
Fx outflow Rs m1259,042 1.4%   
Net fx Rs m18123,317 0.8%   
CASH FLOW
From Operations Rs m11,7547,759 151.5%  
From Investments Rs m-561-4,783 11.7%  
From Financial Activity Rs m-6,762-3,142 215.2%  
Net Cashflow Rs m4,432-166 -2,669.7%  

Share Holding

Indian Promoters % 39.6 52.0 76.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 11.8 63.6%  
FIIs % 16.8 19.0 88.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.2 209.9%  
Shareholders   16,479 31,796 51.8%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  PLETHICO PHARMA  TTK HEALTHCARE  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS